DIAPEP · Diagnostic Peptide pattern for early stage disease detection
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2005-08-03 → 2009-08-02
- EU contribution
- €247,904
- Participants
- 1
- Scheme
- TOK
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - DIAPEP (Diagnostic peptide pattern for early stage disease detection)
The Marie Curie transfer of knowledge (Tok) project DIAPEP was related to the development and clinical acceptance of mass spectrometric peptide patterns (MSPPs) for diagnostic use. This novel multimarker diagnostic tool was, by the time of the project completion, still at an early stage of development in laboratories and industry. The aim of the project was to develop stable, diagnostically meaningful MSPPs in order to evaluate the approach and, if possible, to convert this tool into a clinically applicable, accepted and approved diagnostic procedure in screening, staging, or treatment follow-up. Philips Research recognised the importance and the potential of molecular imaging and molecular diagnostics in the future of health care. However, diagnostic areas outside of diagnostic imaging, e.g. in vitro diagnostic (IVD), genomics, proteomics, the required biomedical and clinical chemical knowledge as well as the developments of a molecular diagnostics platform required researchers with different background and practical medical experience. The Marie Curie program DIAPEP provided access to such biomedical and biochemical knowledge. Two Marie Curie ToK fellows with experience in proteomics and mass spectrometry worked at Philips Research for 18 months each in close collaboration with local clinical partners. The fellows taught full day courses on MS technology several times to Philips researchers as well as to our clinical partners. They implemented and robotised rigorous quality control procedures to arrive at mass spectrometry results that were sufficiently accurate to be of clinical relevance. Our fellows became an essential, integrated and important part of our clinical programme aiming to: 1. discover novel diagnostic patterns suitable to distinguish prostate cancer patients from healthy persons and: 2. to monitor host response in sepsis using a mouse animal model. The entire topic was novel to Philips Research at project start-up and the input by the two fellows was essential to develop protocols for tissue, serum and urine samples, to establish quality control measures and to properly analyse corresponding results. Four invention disclosures, several poster presentations and conference contributions resulted from the activities of the fellows. Based on this Marie-Curie project Philips Research developed to a much better position to assess the value of SELDI-ToF-mass spectrometry and MSPP with respect to its usefulness in diagnostics and was furthermore able to compare this approach with alternative mass spectrometry technologies. One of the fellows was offered a position at Philips Research after her Marie Curie fellowship in order to continue corresponding scientific investigations, thus indicating the level of impact and appreciation the program had.
Data: CORDIS, © European Union
Project objective
Cancer is one of the most common diseases. Because it is only diagnosed after serious patient symptoms, earlier detection of cancer and earlier treatment can result in patient benefits and reduction of healthcare costs. The approach to go for an earlier treatment requires diagnosis with more sensitive equipment and new ways of diagnosis. For this the use of proteomics to identify prognostic markers for cancer diagnosis is relevant. This multi-analyte technique offers the potential to utilize not only single markers, but also to base a diagnosis on marker combinations. These act as a statistically fingerprint" to discriminate between patient groups.Profiling peptides of bodily fluids by mass spectrometry (MS), followed by data mining for MS patterns indicative of diseases in an early stage is seen as a very promising, cost effective approach with diagnostic potential. Also, the combination of this with diagnostic imaging (DI) is even more interesting; this combination to screen and pre-select patients before using imaging optimises the related costs. This ToK proposal is part of the development and clinical acceptance of mass spectrometric peptide patterns (MSPPs) for diagnostic use. This tool is presently still in a research phase in laboratories. Philips considers this project part of a larger scheme to evaluate, improve, and commercialise MSPP as a tool linked to its imaging technologies (both diagnostic and animal imaging).The areas of proteomics, biomedical and clinical chemical knowledge as well as the dev. of a molecular diagnostic platform require researchers with different background and practical medical experience. Currently, Philips has no access to such background or the experience for medical trials. This proposal aims at getting access to this knowledge by hosting two researchers. We plan to combine MSPP-related know-how then available within the MC project with materials, technologies, and procedures available at Philips Research Aachen."
Original text from CORDIS.
Participants
- PHILIPS GMBH FORSCHUNGSLABORATORIEN · AACHENCoordinatorCity levelGermany
Links
Data: CORDIS, © European Union